Argon Laser Trabeculoplasty vs. Standard Topical Medication for Newly Diagnosed Open-Angle Glaucoma
Data Collection
Eye Diseases+1
+ Glaucoma
+ Glaucoma, Open-Angle
Treatment Study
Summary
Study start date: January 1, 1984
Actual date on which the first participant was enrolled.The Glaucoma Laser Trial (GLT) is a study focused on a common eye condition called open-angle glaucoma. This condition often requires treatment beyond just medication. The GLT is exploring the effectiveness of a procedure known as argon laser trabeculoplasty (ALT), which involves applying tiny laser burns around the eye's drainage system. The goal is to understand if ALT can help manage glaucoma better, potentially reducing the need for medication. The study involves individuals newly diagnosed with primary, open-angle glaucoma, aiming to improve their care and address the challenges posed by this condition. During the study, each participant receives ALT in one eye and standard eye drops in the other. The selection of which eye gets which treatment is random. The ALT procedure is done in two sessions, a month apart. Participants then have regular check-ups every three months for at least two years. These check-ups include eye pressure and visual acuity tests, visual field examinations, and disc stereo photographs. Based on the results, the treatment may be adjusted. If the eye pressure isn't reduced as desired, changes to medication or further treatment may be necessary.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 35 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
At the time of recruitment, patients had to be at least 35 years old with an intraocular pressure of at least 22 mm Hg or greater in each eye and evidence of optic nerve damage in at least one eye.